Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models

被引：0

作者：

Cortellino, S. ^{[1
]}

Quagliariello, V. ^{[2
]}

Delfanti, G. ^{[3
]}

Blazevits, O. ^{[4
]}

Chiodoni, C. ^{[5
]}

Maurea, N. ^{[2
]}

Di Mauro, A. ^{[6
]}

Tatangelo, F. ^{[6
]}

Pisati, F. ^{[7
]}

Shmahala, A. ^{[1
]}

Lazzeri, S. ^{[4
]}

Spagnolo, V. ^{[1
]}

Visco, E. ^{[4
]}

Tripodo, C. ^{[8
]}

Casorati, G. ^{[9
]}

Della Bona, P. ^{[10
]}

Longo, V. ^{[11
]}

机构：

[1] IFOM, Dept Med, IEO Campus, Milan, Italy

[2] Ist Nazl Tumori IRCCS Fdn Pascale, Div Cardiol, Naples, Italy

[3] IRCCS Osped San Raffaele, Med Oncol, Milan, Italy

[4] IFOM, Med Oncol, IEO Campus, Milan, Italy

[5] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Milan, Italy

[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Pathol Unit, Naples, Italy

[7] Cogentech SB Srl, Dept Med, Milan, Italy

[8] Univ Palermo, Dept Med, Palermo, Italy

[9] IRCCS San Raffaele Sci Inst, Med Oncol, Milan, Italy

[10] IRCCS San Raffaele Sci Inst, Dept Med, Milan, Italy

[11] USC Inst Global Hlth, Gerontol Dept, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2207

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1068P

引用

页码：S644 / S644

页数：1

共 50 条

[1] Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in preclinical melanoma models
Quagliariello, Vincenzo
Cortellino, Salvatore
Delfanti, Gloria
Di Mauro, Annabella
Tatangelo, Fabiana
Spagnolo, Vanessa
Visco, Euplio
Casorati, Giulia
Chiodoni, Claudia
Della Bona, Paolo
Blazevits, Olga
Ascierto, Paolo Antonio
Maurea, Nicola
Longo, Valter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Activity of Anti-PD-1 in Murine Tumor Models: Role of "Host" PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4
Korman, Alan
Chen, Bing
Wang, Changyu
Wu, Linda
Cardarelli, Pina
Selby, Mark
JOURNAL OF IMMUNOLOGY, 2007, 178
[3] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Ellebaek, Eva
Khan, Shawez
Bastholt, Lars
Schmidt, Henrik
Haslund, Charlotte Aaquist
Donia, Marco
Svane, Inge Marie
EUROPEAN JOURNAL OF CANCER, 2024, 198
[4] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
Reck, Martin
ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
[5] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
Robert, Caroline
Mateus, Christina
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
[6] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
Reddy, Swathi B.
Possick, Jennifer D.
Kluger, Harriet M.
Galan, Anjela
Han, Dale
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
[7] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
Kaehler, Katharina C.
Hassel, Jessica C.
Heinzerling, Lucie
Loquai, Carmen
Moessner, Rotraut
Ugurel, Selma
Zimmer, Lisa
Gutzmer, Ralf
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07): : 662 - 681
[8] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
Kudo, Masatoshi
LIVER CANCER, 2019, 8 (06) : 413 - 426
[9] Experimental bladder cancer is eradicated by combined administration of CpG with anti-CTLA-4 or anti-PD-1, but not with anti-PD-L1
Mangsbo, Sara
Sadeghi, Arian
Korman, Alan
Loskog, Angelica
Totterman, Thomas
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2008, 68 (02) : 212 - 212
[10] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Subrahmanyam, Priyanka
Dong, Zhiwan
Gusenleitner, Daniel
Giobbie-Hurder, Anita
Severgnini, Mariano
Zhou, Jun
Manos, Michael
Maecker, Holden
Hodi, F. Stephen
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

← 1 2 3 4 5 →